Insurance-mandated delays kept a Wisconsin artist from receiving her critical MS medication for months—spotlighting how cost-saving policies like ‘step therapy’ can put patients’ long-term health in jeopardy.
When Serena Hostvet, a 43-year-old artist from Eau Claire, Wisconsin, could no longer draw simple sketches due to her tremors, it threatened not just her craft, but her livelihood and identity. Living with relapsing-remitting multiple sclerosis (RRMS), Hostvet faced a new challenge: her insurer would not immediately approve the medication her doctors said was essential to preventing further nerve damage.
Her story brings into sharp focus the stakes of insurance practices like step therapy—where patients are required to try less costly drugs and fail on those before insurance covers more effective, but pricier, options. In Hostvet’s case, that meant months without the disease-modifying therapy her neurologists prescribed—a period fraught with risk for permanent health decline.
The Origins and Impact of Step Therapy
Known as step therapy or “fail first” protocols, these policies are now deeply entrenched in U.S. health insurance. Nearly six out of ten health plans employ step therapy in some form: a 2021 study put the figure at up to 57.5% across the industry (Health Affairs).
This approach can make financial sense for insurers, especially as specialty drug prices soar. But for patients with progressive, disabling illnesses—such as multiple sclerosis—delays in optimal therapy increase the risk of irreversible damage. According to medical experts, “each attack has the potential for permanent damage.” Every delay, even of a single day, can threaten a patient’s functional abilities and future independence.
What Happened in Wisconsin—and Why It Matters Nationwide
Hostvet’s ordeal began as she cycled through insurer-mandated, lower-cost drugs. Dimethyl fumarate—one such drug—caused her severe digestive distress and flushing. Another, teriflunomide, blurred her vision and disrupted her color perception. When her doctors escalated her case and recommended Ocrevus—a targeted IV therapy—their request triggered multiple rounds of denials and appeals with Anthem Blue Cross and Blue Shield.
Hostvet’s advocates supplied extensive documentation, yet it took nearly two months for the insurer to confirm she’d fulfilled the step therapy prerequisites. Only then did approval come, allowing her first Ocrevus infusion—though by then, she’d spent nearly a quarter of a year at risk for relapse and irreversible harm.
The Ethics and Real-World Toll of Cost Controls
National patient advocacy organizations caution that Hostvet’s experience is not unique. Bari Talente, executive vice president at the National Multiple Sclerosis Society, highlighted that even brief delays intensify anxiety and long-term risk for those with chronic, relapsing illnesses. For her, “it can be very challenging and potentially damage someone’s health.”
The treating neurologists on Hostvet’s team—and experts like Dr. Fred Lublin of Mount Sinai—acknowledge the need for insurers to manage costs, but emphasize that each insurance-driven delay is measured not just in dollars, but in months or years of lost function for patients. They reiterate the clinical reality: relapses do not always fully heal, and repeated attacks cumulatively strip away quality of life.
A Growing Public Health Dilemma
The clash between insurer cost containment and patient well-being is particularly stark in diseases like MS that strike in the prime of life and require expensive, long-term therapies:
- Hostvet’s prescribed drug, Ocrevus, costs nearly $79,000 per year (Health Affairs), out of reach for most patients without insurance coverage.
- Step therapy can require months or years of suboptimal treatment, increasing long-term health costs due to hospitalizations or disability.
- For chronic autoimmune conditions, effective early intervention is crucial to saving function—but cost-saving bureaucratic delays threaten to undermine those gains for thousands of Americans each year.
Hostvet’s experience epitomizes a national debate: balancing insurance solvency against the real-life costs those policies inflict on people in need. While her doctors, advocates, and ultimately her insurer worked to secure the treatment, the ordeal left scars—practical, financial, and emotional.
The Human Cost—and What Comes Next
For Hostvet, finally receiving her infusion brought palpable relief—but also raised questions about what it will take for U.S. health policy to adapt to the needs of people with complex, chronic illnesses. Her message for others fighting similar battles: “It’s exhausting, but don’t stop… There will be someone out there to help.”
This case serves as a warning: Until systemic reforms rebalance financial stewardship and patient urgency, stories like Hostvet’s will continue to unfold, with life-changing consequences for families nationwide.
For in-depth, expert coverage of the most pressing health and policy stories—as they break—continue following onlytrustedinfo.com for analysis you can act on, first.
